f

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Excepteur sint lorem cupidatat.

You may like:

Crafting Psoriatic Arthritis (PsA) Care: From Case Simulation to Practice

Crafting Psoriatic Arthritis (PsA) Care: From Case Simulation to Practice

Crafting Psoriatic Arthritis (PsA) Care: From Case Simulation to Practice

Providing patient-centered care for patients with psoriasis and psoriatic arthritis (PsA) is truly a craft, requiring conscious reflection and deliberate practice. This 60-minute online CME activity begins with a short presentation on the pathophysiology and treatment of PsA, with a focus on new and emerging targeted therapies and patient-provider shared decision making. Participants will then complete 2 patient case simulations in which they will be able to apply their new knowledge, gain hands-on experience, and learn from outcomes related to their treatment decisions.

  • Allan Gibofsky, MD, JD, MACR, FACP, FCLM

    Allan Gibofsky, MD, JD, MACR, FACP, FCLM
    Professor of Medicine, Healthcare Policy and Research
    Weill Cornell Medicine
    Attending Physician and Rheumatologist
    New York-Presbyterian Hospital
    Hospital for Special Surgery
    New York, New York

  • Richard Martin, MD, MA

    Richard Martin, MD, MA
    Professor of Medicine and Rheumatology,
    Michigan State University College of Human Medicine
    East Lansing, Michigan

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative):
    • Marianna Shershneva, MD, PhD; Valerie Siclari, PhD; and Megan Ragan

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Richard Martin, MD, MA
    • Contracted Research/Current Clinical Trials: AbbVie, Amgen, Eicos, Eli Lilly
  • Presenter: Allan Gibofsky, MD, JD, MACR, FACP, FCLM
    • Consulting Fee: AbbVie, Celgene, Merck, Pfizer, Lilly, Novartis, Sandoz
    • Speakers Bureau: AbbVie, Celgene, Pfizer, Lilly, Novartis
    • Advisory Board: AbbVie, Celgene, Pfizer, Sandoz, Samumed
    • Ownership Interest: AbbVie, Amgen, Pfizer, Johnson & Johnson
  • Planner: Linda Grinnell-Merrick, MS, NP-BC
    • Advisory Board: AbbVie, Novartis, Pfizer, Horizon
    • Contracted Research: Novartis
    • Speakers Bureau: AbbVie, Celgene, Novartis, Janssen

As a result of participation in this educational activity, participants should increase their ability to:

  • Discuss mechanisms of action and clinical trial data for new and emerging targeted therapies for PsA

  • identify

    Select appropriate therapies for PsA based on disease domains

  • Engage

    Engage patients with PsA in shared decision making when discussing treatment goals, developing treatment plans, and making treatment modifications

Activity Information

Target Audience
The target audience for this activity is rheumatologists and nurse practitioner/physician assistant rheumatology providers. Other healthcare professionals who treat patients with PsA may benefit from participation.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity is approved for 1.02 contact hour(s) of continuing education (which includes up to .52 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20024118. This activity was planned in accordance with AANP CE Standards and Policies.  

IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 1.00 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.  

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose. 

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs. 

Provider
This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Association.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.